Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed
-
- Nonomura Ayami
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Tamori Akihiro
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Hai Hoang
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Kozuka Ritsuzo
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Fujii Hideki
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Uchida-Kobayashi Sawako
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Enomoto Masaru
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
-
- Kawada Norifumi
- Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan
この論文をさがす
抄録
<p>Glecaprevir/pibrentasvir (GLE/PIB) is a pan-genotype anti-hepatitis C virus (HCV) therapy with high efficacy and safety. However, evidence supporting retreatment following failure of the GLE/PIB regimen is limited. We herein report 3 non-cirrhotic cases involving two men aged 51 and 58 years old and a woman aged 68 years old infected with HCV genotype 1a, 2a, and 3b respectively who failed anti-HCV therapies including GLE/PIB therapy. With combination therapy of sofosbuvir/velpatasvir plus ribavirin (SOF/VEL+RBV) for 24 weeks, all 3 patients had achieved a sustained viral response (SVR) at 24 weeks after completing treatment. SOF/VEL+RBV therapy was effective for retreatment of HCV after failure of GLE/PIB therapy. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 60 (21), 3441-3445, 2021-11-01
一般社団法人 日本内科学会